U.S. markets closed

S&P 500
4,247.44
+8.26(+0.19%)
Dow 30
34,479.60
+13.36(+0.04%)
Nasdaq
14,069.42
+49.09(+0.35%)

Arena Pharmaceuticals, Inc. (ARNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

65.19+0.53 (+0.82%)

At close: 4:00PM EDT

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Commodity Channel Index

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	64.66
Open	64.71
Bid	63.25 x 1400
Ask	70.70 x 800
Day's Range	63.76 - 65.67
52 Week Range	59.55 - 90.19
Volume	405,683
Avg. Volume	456,646

Market Cap	3.957B
Beta (5Y Monthly)	0.53
PE Ratio (TTM)	N/A
EPS (TTM)	-7.40
Earnings Date	Aug 03, 2021 - Aug 09, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	97.53

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

Research Reports

Zacks
Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE
The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.
Zacks
Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel
Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.
- ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML
  GlobeNewswire
- Aptose Presents Highlights from EHA During Corporate Update Event
  GlobeNewswire
Business Wire
Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of eosinophilic esophagitis (EoE).